Sanofi Drug Shows Mixed Results in Genetic Disease Trials

Sanofi announced mixed outcomes for its experimental genetic disorder treatment, venglustat. The drug showed promise in a late-stage study involving patients with type 3 Gaucher disease, significantly improving neurological symptoms like speech and coordination compared to existing therapies.

However, venglustat did not achieve statistical success in a concurrent trial for Fabry disease. While it aided in reducing neuropathic and abdominal pain, the results were not conclusive, potentially due to a strong placebo effect. Sanofi is analyzing the data and consulting with global regulators.

This experimental oral therapy is designed to combat inherited conditions stemming from enzyme deficiencies that cause toxic substance buildup. Sanofi is banking on its late-stage pipeline, including venglustat, to drive future sales growth, especially as its leading eczema and asthma drug approaches patent expiration.

The drug's mechanism involves blocking the accumulation of harmful fatty molecules. If approved, venglustat could become the first treatment to address neurological symptoms in Gaucher disease with an oral dosing option, offering a significant advantage for patients.